AGEs交联蛋白裂解剂的研究进展

• 作 者: 崔浩 钟武 李松
• 机 构: 北京毒物药物研究所,北京毒物药物研究所,北京毒物药物研究所 北京100850,北京100850,北京100850
• 出 处: 军事医学科学院院刊
• 发表日期: 2004年02期
• 关键词: 晚期糖基化终产物 AGEs裂解剂 ALT-711 糖尿病 葡萄糖

葡萄糖和其他还原糖与蛋白的非酶糖基化反应导致晚期糖基化终产物 (advancedglycosylationendproducts,AGEs)以及由AGEs引发的蛋白交联物的形成 ,这是糖尿病和衰老过程中引起并发症的主要原因。动物模型和临床前实验表明AGEs抑制剂以及AGEs交联结构裂解剂 ,如ALT 711,可以从不同的阶段打断AGEs的形成 ,特别是AGEs裂解剂能够逆转或软化由AGEs造成的组织、器官以及血管的硬化 ,因而有希望成为一类新型治疗药物 ,用于治疗糖尿病和衰老过程中由于AGEs引发的各种并发症

Non-enzymatic glycosylation of glucose and other reducing sugars with proteins leads to the formation of advanced glycosylation end products (AGEs) and cross-linked proteins that are triggered by AGEs, which are the major contributors to complications during diabetes and aging the reason. Animal models and preclinical experiments show that AGEs inhibitors and cross-linking agents such as ALT 711, AGEs inhibitors, can interrupt the formation of AGEs at different stages. In particular, AGEs lysates can reverse or soften tissues, organs and, Vascular sclerosis and therefore hope to become a new class of therapeutic drugs for the treatment of diabetes and aging process due to various complications caused by AGEs